Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
When Burger King Corporation began franchising in 1959, it used a regional model where franchisees purchased the right to open stores within a geographic region. These franchise agreements granted BKC very little oversight control of its franchisees and resulted in issues of product quality control, store image and design, and operational procedures. During the 1970s, structural deficiencies in Burger King's franchise system became increasingly problematic for Pillsbury. A major example was the relationship between Burger King and Louisiana-based franchisee Chart House, Burger King's largest franchisee group at the time with over 350 locations in the United States. The company's owners, William and James Trotter, made several moves to take over or acquire Burger King during the 1970s, all of which were spurned by Pillsbury. After the failed attempts to acquire the company, the relationship between Chart House and Burger King soured and eventually devolved into a lawsuit. Chart House eventually spun off its Burger King operations in the early 1980s into a holding company called DiversiFoods which, in turn, was acquired by Pillsbury in 1984 and absorbed into Burger King's operations. As part of the franchising reorganization segment of Operation Phoenix, Donald N. Smith initiated a restructuring of future franchising agreements in 1978.
=== Laboratory findings === These include regenerative anaemia, spherocytosis, icteric plasma, leukopenia due to neutropenia, thrombocytopenia, eosinopenia and bilirubinuria. The alanine aminotransferase, aspartate aminotransferase and creatine kinase levels may be raised. The gamma-glutamyltransferase, urea and creatinine levels remain normal.
=== Teaser tracks on social media === A video of Williams dancing to a song from the album was posted to Instagram by Gabriel Moses in August 2024. Pusha T posted a video to his Instagram account on May 7, 2025, captioned with the song title "So Far Ahead". The video, serving as a trailer for the song, featured footage of him getting ready for the 2025 edition of the Met Gala, spliced with images of figures like slave William Lee, boxer and activist Muhammad Ali, and artist Jean-Michel Basquiat. "So Be It" was previewed on Instagram Live by DJ Hed, and on radio station Hot 97 by disc jockey Funkmaster Flex, both on June 16, a day before the song's official release as a music video. Athlete LeBron James took to Instagram on June 23 to preview Nas' guest verse on "Let God Sort Em Out / Chandeliers."
Its half-life must be long enough so that it will release energy at a relatively constant rate for a reasonable amount of time. The amount of energy released per time (power) of a given quantity is inversely proportional to half-life. An isotope with twice the half-life and the same energy per decay will release power at half the rate per mole. Typical half-lives for radioisotopes used in RTGs are therefore several decades, although isotopes with shorter half-lives could be used for specialized applications. For spaceflight use, the fuel must produce a large amount of power per mass and volume (density). Density and weight are not as important for terrestrial use, unless there are size restrictions. The decay energy can be calculated if the energy of radioactive radiation or the mass loss before and after radioactive decay is known. Energy release per decay is proportional to power production per mole. Radiation must be of a type easily absorbed and transformed into thermal radiation, preferably alpha radiation. Beta radiation can emit considerable gamma/X-ray radiation through bremsstrahlung secondary radiation production and therefore requires heavy shielding. Isotopes must not produce significant amounts of gamma, neutron radiation or penetrating radiation in general through other decay modes or decay chain products. The first two criteria limit the number of possible fuels to fewer than thirty nuclides within the entire table of nuclides.
== Structure == Erythroferrone in humans is transcribed as a precursor of 354 amino acids, with a signal peptide of 28 amino acids. The mouse gene encodes a 340 amino acid protein which is 71% identical. Homology is greater at the C-terminal where there is a TNF-alpha-like domain. As a member of the C1q/TNF-Related Protein (CTRP) family, erythroferrone has a 4-domain structure with a unique N-terminus. The two larger domains are connected by a short, proline-rich, collagenous linker that is thought to promote protein multimerization. Erythroferrone is predicted to contain two PCSK3/furin recognition sites. The protein hormone weighs approximately 35-40 kDa.
Sources: en.wikipedia.org
==== Bevacizumab ==== Through binding to VEGFR and other VEGF receptors in endothelial cells, VEGF can trigger multiple cellular responses like promoting cell survival, preventing apoptosis, and remodeling cytoskeleton, all of which promote angiogenesis. Bevacizumab (brand name Avastin) traps VEGF in the blood, lowering the binding of VEGF to its receptors. This results in reduced activation of the angiogenesis pathway, thus inhibiting new blood vessel formation in tumors. After a series of clinical trials in 2004, Avastin was approved by the FDA, becoming the first commercially available anti-angiogenesis drug. FDA approval of Avastin for breast cancer treatment was later revoked on November 18, 2011.
=== Privacy and fungibility === Bitcoin is pseudonymous, with funds linked to addresses, not real-world identities. While the owners of these addresses are not directly identified, all transactions are public on the blockchain. Patterns of use, like spending coins from multiple inputs, can hint at a common owner. Public data can sometimes be matched with known address owners. Bitcoin exchanges might also need to collect personal data as per legal requirements. For enhanced privacy, users can generate a new address for each transaction. In the bitcoin network, each bitcoin is treated equally, ensuring basic fungibility. However, users and applications can choose to differentiate between bitcoins. While wallets and software treat all bitcoins the same, each bitcoin's transaction history is recorded on the blockchain. This public record allows for chain analysis, where users can identify and potentially reject bitcoins from controversial sources. For example, in 2012, Mt. Gox froze accounts containing bitcoins identified as stolen.
=== Nanoscale and spectroscopy below the diffraction limit === The spatial resolution of FTIR can be further improved below the micrometer scale by integrating it into scanning near-field optical microscopy platform. The corresponding technique is called nano-FTIR and allows for performing broadband spectroscopy on materials in ultra-small quantities (single viruses and protein complexes) and with 10 to 20 nm spatial resolution.
Plutonium-238, curium-244, strontium-90, and most recently americium-241 are the most often cited candidate isotopes, but 43 more isotopes out of approximately 1,300 were considered at the beginning in the 1950s. The table below does not necessarily give power densities for the pure material but for a chemically inert form. For actinides this is of little concern as their oxides are usually inert enough (and can be transformed into ceramics further increasing their stability), but for alkali metals and alkaline earth metals like caesium or strontium respectively, relatively complex (and heavy) chemical compounds have to be used. For example, strontium is commonly used as strontium titanate in RTGs, which increases molar mass by about a factor of 2. Furthermore, depending on the source, isotopic purity may not be obtainable. Plutonium extracted from spent nuclear fuel has a low share of Pu-238, so plutonium-238 for use in RTGs is usually purpose-made by neutron irradiation of neptunium-237, further raising costs. Caesium in fission products is almost equal parts Cs-135 and Cs-137, plus significant amounts of stable Cs-133 and, in "young" spent fuel, short lived Cs-134. If isotope separation, a costly and time-consuming process, is to be avoided, this has to be factored in, too. While historically RTGs have been rather small, there is in theory nothing preventing RTGs from reaching into the megawattthermal range of power.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。